Krystal Biotech (KRYS) EBITDA Margin (2021 - 2025)
Historic EBITDA Margin for Krystal Biotech (KRYS) over the last 4 years, with Q3 2025 value amounting to 81.09%.
- Krystal Biotech's EBITDA Margin rose 461100.0% to 81.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 53.19%, marking a year-over-year increase of 307300.0%. This contributed to the annual value of 30.4% for FY2024, which is 61500.0% up from last year.
- Latest data reveals that Krystal Biotech reported EBITDA Margin of 81.09% as of Q3 2025, which was up 461100.0% from 40.71% recorded in Q2 2025.
- Krystal Biotech's 5-year EBITDA Margin high stood at 1059.99% for Q1 2021, and its period low was 0.01% during Q1 2024.
- Over the past 4 years, Krystal Biotech's median EBITDA Margin value was 40.94% (recorded in 2025), while the average stood at 229.27%.
- As far as peak fluctuations go, Krystal Biotech's EBITDA Margin plummeted by -9070600bps in 2024, and later skyrocketed by 461100bps in 2025.
- Krystal Biotech's EBITDA Margin (Quarter) stood at 1059.99% in 2021, then tumbled by -98bps to 23.04% in 2023, then skyrocketed by 108bps to 48.05% in 2024, then skyrocketed by 69bps to 81.09% in 2025.
- Its EBITDA Margin stands at 81.09% for Q3 2025, versus 40.71% for Q2 2025 and 41.17% for Q1 2025.